Status:
ACTIVE_NOT_RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Lead Sponsor:
AbbVie
Conditions:
Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
Eligibility Criteria
Inclusion
- Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
- Male subject agrees to refrain from sperm donation.
- Female subjects must not be pregnant or breastfeeding.
Exclusion
- \- None.
Key Trial Info
Start Date :
September 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2026
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT03844048
Start Date
September 6 2019
End Date
February 1 2026
Last Update
July 18 2025
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona Cancer Center - Tucson /ID# 210548
Tucson, Arizona, United States, 85724
2
UCLA Santa Monica Hematology Oncology /ID# 210551
Los Angeles, California, United States, 90095
3
Ingalls Memorial Hosp /ID# 210553
Harvey, Illinois, United States, 60426
4
Dana-Farber Cancer Institute /ID# 215360
Boston, Massachusetts, United States, 02215